CD274 and cancer: “Two-half” antibodies have also been developed using other platforms, for example, the biparatopic anti-HER2 antibody MBS301 by Mabworks currently in phase 1 (NCT03842085), the anti- BCMA/CD3 Elranatamab (PF-06863135) by Pfizer in phase 2 for r/r MM (NCT04649359), the anti-PD1/PD-L1 IBI318 by Innovent in several phase 1/2 trials for advanced tumors, alone or combined with lenvatinib or chemotherapy (see Supplementary Table S1), and the anti-PD1/PD-L1 LY3434172 based on Zymeworks’ Azymetric platform in phase I testing also for advanced cancers (NCT03936959) [97].